{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:30:29Z","timestamp":1793784629415,"version":"4.6.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiparametric MRI (mpMRI) using the Prostate Imaging Reporting and Data System (PI-RADS v2.1) is widely used for prostate cancer evaluation but is limited by interobserver variability. The PRIMARY score standardizes intraprostatic prostate-specific membrane antigen (PSMA) PET interpretation; however, data using 18F-PSMA-1007, particularly in sub-Saharan Africa, remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To compare the diagnostic performance of\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/computed tomography (CT) and mpMRI and evaluate the association of primary lesion standardized uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ) and PRIMARY score with adverse clinicopathologic features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 61 men with biopsy-confirmed prostate cancer who underwent both\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT and mpMRI between January 2023 and February 2025. PRIMARY and PI-RADS scores were assigned from PET\/CT and mpMRI, respectively. Histopathology served as the reference standard. Sensitivity, positive predictive value (PPV), diagnostic accuracy, and associations between SUV\n                      <jats:sub>max<\/jats:sub>\n                      and clinicopathologic features were analyzed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PET\/CT demonstrated sensitivity of 88.3% and diagnostic accuracy of 86.9%, comparable to mpMRI (86.7 and 85.3%, respectively). Both modalities showed a PPV of 98.1%. SUV\n                      <jats:sub>max<\/jats:sub>\n                      greater than or equal to 12 was significantly associated with nodal metastases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.040), distant metastases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028), higher Gleason score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.015), elevated prostate specific antigen (PSA;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018), seminal vesicle invasion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), and bladder or rectal invasion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.036). Higher PRIMARY scores also trended toward higher Gleason grade and PSA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-PSMA-1007 PET\/CT demonstrated diagnostic performance comparable to mpMRI. SUV\n                      <jats:sub>max<\/jats:sub>\n                      greater than or equal to 12 (PRIMARY score 5) was associated with aggressive clinicopathologic features, supporting the applicability of the PRIMARY score framework in this sub-Saharan African cohort.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002202","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:26Z","timestamp":1783414826000},"page":"1331-1338","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of 18F-prostate-specific membrane antigen-1007 PET\/computed tomography and multiparametric MRI in prostate cancer: application of the PRIMARY score in a sub-Saharan African cohort"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8050-744X","authenticated-orcid":false,"given":"Poonamjeet Kaur","family":"Loyal","sequence":"first","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Olwit","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmit","family":"Shah","sequence":"additional","affiliation":[{"name":"Internal Medicine"},{"name":"Brain and Mind Institute, Aga Khan University Hospital, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Mwania","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Makhdomi","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel Nguku","family":"Gitau","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5534\/wjmh.210070","article-title":"Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview.","volume":"40","author":"Hinata","year":"2022","journal-title":"World J Mens Health"},{"key":"R3-20261104","first-page":"485","article-title":"Prostate cancer statistics, 2025.","volume":"75","author":"Kratzer","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"100427","DOI":"10.1016\/j.jcpo.2023.100427","article-title":"Prostate cancer screening uptake in Kenya: an analysis of the demographic and health survey.","volume":"37","author":"Okyere","year":"2023","journal-title":"J Cancer Policy"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4314\/aas.v18i3.2","article-title":"Barriers and facilitators to uptake of prostate cancer screening in a Kenyan rural community.","volume":"18","author":"Mbugua","year":"2021","journal-title":"Ann Afr Surg"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMc2000069","article-title":"Racial differences in genomic profiling of prostate cancer.","volume":"383","author":"Mahal","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis.","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4314\/aas.v19i2.8","article-title":"Utility of multiparametric magnetic resonance imaging as a predictor of clinically significant prostate cancer in a sub-Saharan African population.","volume":"19","author":"Obino","year":"2022","journal-title":"Ann Afr Surg"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2214\/AJR.09.2579","article-title":"Challenges in clinical prostate cancer: role of imaging.","volume":"192","author":"Kelloff","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.","volume":"59","author":"Dickinson","year":"2011","journal-title":"Eur Urol"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: how to manage indeterminate or equivocal PI-RADS 3 lesions?","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl Androl Urol"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00261-019-01919-2","article-title":"False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location.","volume":"44","author":"Stolk","year":"2019","journal-title":"Abdom Radiol (NY)"},{"key":"R13-20261104","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.3390\/cancers14194725","article-title":"Clinical application of the new prostate imaging for recurrence reporting (PI-RR) score proposed to evaluate the local recurrence of prostate cancer after radical prostatectomy.","volume":"14","author":"Ciccarese","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pros.24475","article-title":"The use of 68Ga-PSMA PET\/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.","volume":"83","author":"Yang","year":"2023","journal-title":"Prostate"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of 68Ga-PSMA PET\/CT and multiparametric mri improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis.","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study.","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"R17-20261104","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis.","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2967\/jnumed.123.266164","article-title":"Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database.","volume":"65","author":"Emmett","year":"2024","journal-title":"J Nucl Med"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/diagnostics14131315","article-title":"Diagnostic accuracy of molecular imaging techniques for detecting prostate cancer: a systematic review.","volume":"14","author":"Alshamrani","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.119.234187","article-title":"Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard.","volume":"61","author":"Kuten","year":"2020","journal-title":"J Nucl Med"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging.","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40658-022-00487-7","article-title":"Comparison of image quality and spatial resolution between 18F, 68Ga, and 64Cu phantom measurements using a digital biograph vision PET\/CT.","volume":"9","author":"Braune","year":"2022","journal-title":"EJNMMI Phys"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.euo.2023.04.006","article-title":"Head-to-head comparison of 18F-PSMA-1007 positron emission tomography\/computed tomography and multiparametric magnetic resonance imaging with whole-mount histopathology as reference in localisation and staging of primary prostate cancer.","volume":"6","author":"Exterkate","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"R24-20261104","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1007\/s00259-025-07208-z","article-title":"Prospective comparison of 18F-PSMA-1007 PET\/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer.","volume":"52","author":"Kivikallio","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R26-20261104","first-page":"P362","article-title":"BPH-related false positive of 68Ga-PSMA PET\/CT in the diagnosis of prostate cancer: the Achilles\u2019 heel of biopsy-free radical prostatectomy?","volume":"64","author":"Tang","year":"2023","journal-title":"J Nucl Med"},{"key":"R28-20261104","first-page":"169","article-title":"Correlation of Ga-68 PSMA PET\/CT positivity with gleason scores and serum PSA levels in initial staging of prostate adenocarcinoma, and the contribution of PET\/CT imaging to patient management.","volume":"58","author":"\u00d6zt\u00fcrk","year":"2025","journal-title":"Acta Haematol Oncol Turc"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bju.15710","article-title":"Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with oncological outcomes in patients with prostate cancer.","volume":"129","author":"Bodar","year":"2022","journal-title":"BJU Int"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:00:26Z","timestamp":1793782826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002202","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2026-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}